Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 08:45 ET | Source: Cycurion

Cycurion Launches Strategic Cybersecurity Webinar Series to Fortify Public Sector Defenses

MCLEAN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. ("Cycurion" or the "Company") (NASDAQ: CYCU), a publicly traded leader in technology and staffing solutions for the public sector, today...
October 28, 2025 10:52 ET | Source: Cycurion

Cycurion Shareholder Letter Explains Path to Expanded Margins and Recurring Revenue for 2026

MCLEAN, Va., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading cybersecurity solutions provider, today issued the following press release to...
October 16, 2025 08:45 ET | Source: Cycurion

Cycurion Announces Five New Contracts Totaling $1 Million, Expanding into Commercial Sectors

MCLEAN, Va., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cycurion (NASDAQ: CYCU), a leading provider of cybersecurity solutions, today announced the successful closure of five new contracts in September,...
October 06, 2025 15:19 ET | Source: Robbins LLP

MOH Stockholders: Robbins LLP Reminds Molina Healthcare, Inc. Stockholders of the Class Action Lawsuit

Robbins LLP is Investigating Allegations that Molina Healthcare, Inc. (MOH) Mislead Investors Regarding its Business Prospects.
September 22, 2025 15:41 ET | Source: Robbins LLP

JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.

Robbins LLP is Investigating Allegations that Jasper Therapeutics, Inc. (JSPR) Misled Investors Regarding the Commercial Prospects of its Lead Product
September 22, 2025 04:30 ET | Source: Alvotech

Lyfjastofnun Evrópu mælir með leyfi til markaðssetningar á Gobivaz, fyrirhugaðri hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab)

Mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hefur mælt með því að heimila markaðssetningu AVT05, sem er fyrirhuguð hliðstæða líftæknilyfsins Simponi (golimumab), sem þróuð var af Alvotech....
September 22, 2025 04:30 ET | Source: Alvotech

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
September 19, 2025 07:45 ET | Source: Alvotech

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech

REYKJAVÍK 19. september 2025 - Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji Pharma“),...
September 19, 2025 07:45 ET | Source: Alvotech

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
September 08, 2025 07:00 ET | Source: EDAP TMS S.A.

EDAP Receives HIFU Reimbursement for Prostate Cancer in France

Focal One Robotic HIFU procedure now covered under France’s national universal health systemReimbursement milestone allows increased patient access to Focal One Robotic HIFU AUSTIN, Texas, September...